QUEBEC CITY, Aug. 13 /CNW/ - Medicago Inc. (TSX-V: MDG) today announced that it will be presenting an update of its development of H5N1 vaccines generated from plant-made VLPs and unique technology platform, at the Targeted Immunotherapeutics and Vaccine Summit. This conference will be held from August 13-15, 2008, at the Royal Sonesta Hotel, Cambridge, Massachusetts.

Manon Couture, Ph.D., Project Leader, Product Development and Innovation will deliver a presentation on \"Innovative Influenza Virus-Like Particles Provides Protection against an H5N1 Challenge\" in a session entitled \"Innovating Vaccine Development,\" on Thursday August 14, 2008 at 10:45 a.m. EDT.

Additional information about the Targeted Immunotherapeutics and Vaccines Summit, including the full scientific program, can be viewed at http://www.healthtech.com\">www.healthtech.com